Kringle Pharma (4884) · InitiativeRestated
Outsourced manufacturing through contract manufacturing organizations
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Reliance on an Outsourced Production SystemA theme 44 companies write about · 44 as a headwind · 1 as a tailwind
The whole theme swung hardest in 2020: 4 of 20 companies on the "Worse" side.
21 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 44 companies compared. The sentences above are computed from all 44.Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「２社の製造受託機関に原薬製造及び製剤製造を各々委託することにより、原薬及び製剤の供給を行っております。」
原薬と製剤の製造をそれぞれ外部の製造受託機関へ委託する体制を継続している。 - FY2020First statedAnnual report
「We have expertise in manufacturing recombinant human HGF protein, including both API and drug product manufacturing, and supply products by outsourcing API and drug product manufacturing separately to 2 contract manufacturers.」
Rather than owning manufacturing facilities, the company outsources API and drug product manufacturing separately to contract manufacturers.